Pancreatic Cancer Research

ResearcherSoochow UniversityNo recent work listed

Xuemin Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0529-3346; OpenAlex author ID A5101957487. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 3 papers · 2023: 3 papers

Papers 9

  1. Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.5210↗
  2. SETD8 inhibits ferroptosis in pancreatic cancer by inhibiting the expression of RRAD. Last author DOI 10.1186/s12935-023-02899-6↗
  3. PITX2 in pancreatic stellate cells promotes EMT in pancreatic cancer cells via the Wnt/β-catenin pathway. Last author DOI 10.3724/abbs.2023118↗
  4. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis. Co-author DOI 10.1016/j.prp.2022.153911↗
  5. A multimodal model fusing multiphase contrast-enhanced CT and clinical characteristics for predicting lymph node metastases of pancreatic cancer. Co-author DOI 10.1088/1361-6560/ac858e↗
  6. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial. Co-author DOI 10.1136/bmjopen-2021-057128↗
  7. Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). First author DOI 10.1016/j.hbpd.2020.12.020↗
  8. CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathw… Co-author DOI 10.1093/abbs/gmab032↗
  9. Identification of ENTPD8 and cytidine in pancreatic cancer by metabolomic and transcriptomic conjoint analysis. Last author DOI 10.1111/cas.13733↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaowu Xu · 3 shared papers, 2022–2023 · strength 0.48
  2. Xianjun Yu · 3 shared papers, 2021–2023 · strength 0.39
  3. Yi Qin · 2 shared papers, 2023 · strength 0.34
  4. Di Wu · 2 shared papers, 2021–2023 · strength 0.31
  5. Yue Zhang · 2 shared papers, 2021–2023 · strength 0.31
  6. Shunrong Ji · 2 shared papers, 2023 · strength 0.29
  7. Shutao Pan · 2 shared papers, 2022–2023 · strength 0.25
  8. Jingdong Li · 2 shared papers, 2022–2023 · strength 0.25
  9. Yahui Liu · 2 shared papers, 2022–2023 · strength 0.25
  10. Jun Liu · 2 shared papers, 2022–2023 · strength 0.25
  11. Yang Yang · 1 shared paper, 2023 · strength 0.18
  12. Zekun Lu · 1 shared paper, 2023 · strength 0.17
  13. Bingkai Xiao · 1 shared paper, 2023 · strength 0.17
  14. Qiangsheng Hu · 1 shared paper, 2023 · strength 0.17
  15. Yulan Zhu · 1 shared paper, 2022 · strength 0.15
  16. Lujun Chen · 1 shared paper, 2022 · strength 0.15
  17. Shulong Li · 1 shared paper, 2022 · strength 0.14
  18. Yi Gao · 1 shared paper, 2022 · strength 0.14
  19. Qian Lu · 1 shared paper, 2022 · strength 0.14
  20. Chenjie Zhou · 1 shared paper, 2022 · strength 0.14
  21. Baochun Lu · 1 shared paper, 2021 · strength 0.14
  22. Jie Hua · 1 shared paper, 2021 · strength 0.14
  23. Wei Wang · 1 shared paper, 2021 · strength 0.14
  24. Jin Xu · 1 shared paper, 2021 · strength 0.14
  25. Si Shi · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.